Lung cancer

Immutep Announces Improving Data from the Phase II TACTI-002 Study

Monday, June 1, 2020 - 12:40am

Improving Overall Response Rate (iORR) in HNSCC, increasing to 38.9% (previously 33% iORR)

Key Points: 
  • Improving Overall Response Rate (iORR) in HNSCC, increasing to 38.9% (previously 33% iORR)
    Progression free survival (PFS) continues to improve in 1st line non-small cell lung cancer (NSCLC) patients, estimated at more than 9 months
    SYDNEY, Australia, June 01, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) announces new interim data from its ongoing Phase II TACTI-002 study.
  • This data relates to the cut-off date of 4 May 2020 and shows improving efficacy results.
  • Immutep CSO and CMO, Dr Frederic Triebel said: TACTI-002 is generating increasingly promising data from both the NSCLC and HNSCC arms of study, as patients continue to receive efti in combination with KEYTRUDA.
  • The improving data in both HNSCC and NSCLC patients supports the use of efti in combination with pembrolizumab as a promising new therapeutic option for patients.

Guardant360 test results may provide prognostic information beyond the detection of actionable biomarkers for ALK-rearranged NSCLC patients

Saturday, May 30, 2020 - 12:00pm

The poster presentation is entitled "Longitudinal monitoring of next generation sequencing (NGS) of plasma cell-free DNA in ALK-rearranged NSCLC patients treated with ALK tyrosine inhibitors".

Key Points: 
  • The poster presentation is entitled "Longitudinal monitoring of next generation sequencing (NGS) of plasma cell-free DNA in ALK-rearranged NSCLC patients treated with ALK tyrosine inhibitors".
  • Patients with known ALK positive advanced stage NSCLC had blood collected prior to the start of ALK-targeted treatment, 2 months after treatment began, and when the cancer progressed.
  • The study also found that the co-occurrence of TP53 mutations and ALK alterations in cfDNA prior to treatment was associated with shorter PFS and OS in patients with ALK positive NSCLC.
  • The Guardant360 test is increasingly being used to guide treatment in metastatic lung cancer as the number of treatment-relevant genomic alterations continues to grow.

Guardant360 test results may provide prognostic information beyond the detection of actionable biomarkers for ALK-rearranged NSCLC patients

Saturday, May 30, 2020 - 12:00pm

The poster presentation is entitled "Longitudinal monitoring of next generation sequencing (NGS) of plasma cell-free DNA in ALK-rearranged NSCLC patients treated with ALK tyrosine inhibitors".

Key Points: 
  • The poster presentation is entitled "Longitudinal monitoring of next generation sequencing (NGS) of plasma cell-free DNA in ALK-rearranged NSCLC patients treated with ALK tyrosine inhibitors".
  • Patients with known ALK positive advanced stage NSCLC had blood collected prior to the start of ALK-targeted treatment, 2 months after treatment began, and when the cancer progressed.
  • The study also found that the co-occurrence of TP53 mutations and ALK alterations in cfDNA prior to treatment was associated with shorter PFS and OS in patients with ALK positive NSCLC.
  • The Guardant360 test is increasingly being used to guide treatment in metastatic lung cancer as the number of treatment-relevant genomic alterations continues to grow.

Lilly's CYRAMZA® (ramucirumab) Receives FDA Approval as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

Saturday, May 30, 2020 - 2:07am

These include several studies investigating CYRAMZA in combination with other anti-cancer therapies for the treatment of multiple tumor types.

Key Points: 
  • These include several studies investigating CYRAMZA in combination with other anti-cancer therapies for the treatment of multiple tumor types.
  • CYRAMZA, in combination with erlotinib, for first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations.
  • CYRAMZA, in combination with docetaxel, is indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy.
  • 10Hirsh V. Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors.

Foundation Medicine and Dana-Farber Present Data at ASCO20 Showing that Comprehensive Genomic Profiling Identified Co-Occurring Alterations that May Cause Treatment Resistance in Patients with METex14-altered NSCLC

Friday, May 29, 2020 - 1:05pm

These data underscore the urgent need to identify effective strategies to delay or overcome resistance to targeted therapies in METex14 mutant NSCLC.

Key Points: 
  • These data underscore the urgent need to identify effective strategies to delay or overcome resistance to targeted therapies in METex14 mutant NSCLC.
  • This study emphasizes the importance of comprehensive genomic profiling in patients with METex14-altered NSCLC to facilitate precision medicine both earlier and throughout a patients treatment, said Brian Alexander, M.D., M.P.H, chief medical officer at Foundation Medicine and study co-author.
  • The study also adds more evidence that genomic testing through both tissue and liquid biopsy can be an important tool for monitoring for resistance alterations during treatment.
  • NSCLC accounts for 80-85% of lung cancer diagnoses.1 Mutations that lead to skipping METex14, called skipping alterations, are oncogenic drivers in NSCLC.

IMFINZI® (durvalumab) Showed a Sustained Overall Survival Benefit in 1st-Line Extensive-Stage Small Cell Lung Cancer in the Phase III CASPIAN Trial

Friday, May 29, 2020 - 1:01pm

Monitor patients for signs and symptoms of hepatitis during and after discontinuation of IMFINZI, including clinical chemistry monitoring.

Key Points: 
  • Monitor patients for signs and symptoms of hepatitis during and after discontinuation of IMFINZI, including clinical chemistry monitoring.
  • Withhold IMFINZI for Grade 2 colitis or diarrhea; permanently discontinue for Grade 3 or 4 colitis or diarrhea.
  • CASPIAN is a randomized, open-label, multi-center, global, Phase III trial in the 1st-line treatment of 805 patients with ES-SCLC.
  • Tremelimumab is being tested in a clinical trial program in combination with IMFINZI in NSCLC, bladder cancer, head and neck cancer and liver cancer cancers.

ENHERTU (fam-trastuzumab deruxtecan-nxki) Demonstrated Meaningful Clinical Activity in Patients With HER2-mutant Non-small Cell Lung Cancer in Interim Analysis of Phase II DESTINY-Lung01 Trial

Friday, May 29, 2020 - 1:00pm

The overall safety and tolerability profile of ENHERTU in DESTINY-Lung01 was consistent with that seen in the Phase I lung cancer trial and previously reported ENHERTU trials.

Key Points: 
  • The overall safety and tolerability profile of ENHERTU in DESTINY-Lung01 was consistent with that seen in the Phase I lung cancer trial and previously reported ENHERTU trials.
  • ENHERTU has not been approved in the United States for non-small cell lung cancer.
  • Severe, life-threatening, or fatal interstitial lung disease (ILD), including pneumonitis, can occur in patients treated with ENHERTU.
  • In clinical studies, of the 234 patients with unresectable or metastatic HER2-positive breast cancer treated with ENHERTU, ILD occurred in 9% of patients.

ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung Cancer in Interim Analysis of Phase 2 DESTINY-Lung01 Trial

Friday, May 29, 2020 - 1:00pm

In May 2020, ENHERTU also received a BTD for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a HER2 mutation and with disease progression on or after platinum-based therapy.

Key Points: 
  • In May 2020, ENHERTU also received a BTD for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a HER2 mutation and with disease progression on or after platinum-based therapy.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
  • Severe, life-threatening, or fatal interstitial lung disease (ILD), including pneumonitis, can occur in patients treated with ENHERTU.
  • In clinical studies, of the 234 patients with unresectable or metastatic HER2-positive breast cancer treated with ENHERTU, ILD occurred in 9% of patients.

Caris Life Sciences Showcases Data on KRAS Mutations in Patients With Non-Small Cell Lung and Pancreatic Cancer at ASCO20 Virtual Scientific Program

Friday, May 29, 2020 - 1:00pm

The poster is titled, "Characterization of KRAS mutations (mt) in non-small cell lung cancer (NSCLC)."

Key Points: 
  • The poster is titled, "Characterization of KRAS mutations (mt) in non-small cell lung cancer (NSCLC)."
  • Caris will present additional data from studies highlighting the distinct molecular landscapes of patients across several cancer types, including mesothelioma and gastroesophageal cancers.
  • Caris Life Sciences is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation.
  • Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Asia and other international markets.

eFFECTOR’s Tomivosertib Demonstrates Positive Phase 2 Results for Subjects with Non-Small Cell Lung Cancer in Combination with Checkpoint Inhibitors

Friday, May 29, 2020 - 1:00pm

The data demonstrates tomivosertibs potential as a therapeutic solution for common resistance mechanisms to checkpoint inhibitors.

Key Points: 
  • The data demonstrates tomivosertibs potential as a therapeutic solution for common resistance mechanisms to checkpoint inhibitors.
  • In a Phase 2 study, open-label study, tomivosertib demonstrated antitumor activity in combination with check point inhibitors (CPI) in patients with solid tumors who progressed on CPI treatment.
  • In the study, 41% of patients with non-small cell lung cancer treated with tomivosertib showed progression free survival at 24 weeks.
  • Tomivosertib is being evaluated as an add-on when patients are experiencing insufficient response to an FDA-approved checkpoint inhibitor [ NCT03616834 ].